FDA Advisory Panel Unanimously Backs Moderna's mRNA Flu Vaccine, Setting Stage for First mRNA Seasonal Flu Shot
Key Insights
An FDA external advisory panel voted 9-0 to support Moderna's mFlusiva (search) (mRNA-1010), which would be the first mRNA-based seasonal influenza (search) vaccine in the U.S.
In a trial of over 40,000 adults aged 50 and older, the vaccine reduced symptomatic flu by approximately 27% compared with a standard shot, with stronger effects on hospitalizations and immune responses.
A final FDA decision is expected by August 5, with potential availability for the 2026–2027 flu season.
An FDA external advisory panel has voted unanimously, 9-0, to back Moderna's mFlusiva (search) (mRNA-1010), positioning it to become the first mRNA-based seasonal influenza (search) vaccine in the United States. The vote marks a pivotal regulatory milestone for mRNA technology beyond COVID-19 and signals growing confidence in the platform's versatility for routine immunization.
The panel's endorsement follows a tumultuous review process. The vaccine had previously been flagged when RFK Jr.'s FDA indicated it would not undergo review, only to reverse course after immense backlash and proceed with the advisory committee evaluation.
Clinical Trial Evidence
The recommendation rests on data from a large-scale trial enrolling more than 40,000 adults aged 50 and older. In that study, mFlusiva (search) cut symptomatic influenza (search) by approximately 27% compared with a standard flu shot. Notably, the mRNA vaccine demonstrated a greater effect on hospitalizations and elicited stronger immune responses than even the high-dose senior vaccine currently in use.
The trial's size and focus on older adults—a population at elevated risk for severe influenza (search) complications—lend weight to the panel's favorable assessment of the vaccine's safety and efficacy profile.
Regulatory Timeline and Access Hurdles
A final FDA decision on mFlusiva (search) is expected by August 5. If approved, the vaccine could become available for the 2026–2027 influenza (search) season. However, a significant barrier remains: the United States currently has no functioning Advisory Committee on Immunization Practices (ACIP). Ongoing legal battles between the American Academy of Pediatrics and RFK Jr. have left the committee unable to convene and set policy on vaccine recommendations.
While the FDA may declare the vaccine safe and effective, the absence of ACIP means no federal body is in place to determine who should receive it and when. This gap likely means Americans will not have access to mFlusiva (search) this fall, even with a timely FDA approval.
Broader Implications
The unanimous panel vote represents a major step forward for mRNA vaccine technology in seasonal respiratory disease prevention. Moderna's mFlusiva (search), if ultimately authorized and deployed, would expand the influenza (search) vaccine arsenal at a time when public health systems continue to grapple with the burden of seasonal flu. The outcome also underscores the resilience of the regulatory process, as the vaccine's review proceeded despite initial resistance, ultimately yielding a clear scientific consensus.